kbtbd8 Antibody

What is KBTBD8 and what are its main biological functions?

KBTBD8 (Kelch repeat and BTB domain-containing protein 8) functions as a substrate-specific adapter of the BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex. Unlike many ubiquitin ligases that promote protein degradation, KBTBD8-mediated ubiquitination often stabilizes its substrates . Its biological functions include:

• Regulation of neural crest specification through monoubiquitination of NOLC1 and TCOF1

• Maintenance of female fertility by regulating PKM1 levels in oocytes

• Potential role in epithelial ovarian cancer (EOC) progression

The protein contains both BTB (Broad-Complex, Tramtrack and Bric a brac) and Kelch repeat domains, which facilitate protein-protein interactions and substrate recognition respectively.

How do I select the appropriate KBTBD8 antibody for my research?

Selection of an appropriate KBTBD8 antibody depends on several experimental factors:

• Target species: Confirm species cross-reactivity - available antibodies react with human, mouse, rat, and other species depending on the manufacturer

• Application requirements: Choose antibodies validated for your specific application:

  • Western blotting (WB)

  • Immunohistochemistry (IHC)

  • Immunofluorescence (IF)

  • Flow cytometry (FACS)

  • ELISA

• Epitope specificity: Consider antibodies targeting different regions of KBTBD8:

  • N-terminal region

  • C-terminal region

  • Specific amino acid sequences (e.g., AA 264-464)

• Clonality preference:

  • Monoclonal: Higher specificity, consistent lot-to-lot reproducibility

  • Polyclonal: Recognize multiple epitopes, potentially higher sensitivity

• Validation data: Review provided validation data for expected band size (~69 kDa) and specificity in tissues relevant to your research.

What experimental approaches are effective for studying KBTBD8 function in cellular processes?

Based on published methodologies, effective approaches include:

Knockdown/Knockout Studies:

• siRNA or sgRNA-mediated KBTBD8 depletion to assess phenotypic consequences

• Antibody-mediated depletion for acute protein reduction

Overexpression Studies:

• Full-length CDS cloning into expression vectors (e.g., pcDNA3.1)

• Flag-tagged or EGFP-fusion constructs for tracking expression

Protein Interaction Studies:

• Co-immunoprecipitation (Co-IP) to identify KBTBD8 binding partners (e.g., CUL3)

• Protein network analysis to map KBTBD8 interactions

Functional Assays:

• Cell proliferation assays (e.g., CCK-8)

• Migration assays (e.g., wound healing)

• Apoptosis assessment

• ATP level measurement and mitochondrial membrane potential analysis

• ROS generation measurement

Transcriptomic Analysis:

• RNA sequencing to identify gene expression changes following KBTBD8 manipulation

How can I effectively validate KBTBD8 antibody specificity for my experiments?

To ensure experimental rigor, validate KBTBD8 antibody specificity through multiple approaches:

• Positive and negative controls:

  • Positive controls: Tissues/cells known to express KBTBD8 (e.g., ovarian tissue, HT-1080 cells, A431 cells)

  • Negative controls: KBTBD8 knockdown/knockout cells or tissues

• Multiple detection methods:

  • Compare results between different antibody clones targeting different epitopes

  • Cross-validate using multiple techniques (Western blot, IHC, IF)

• Peptide competition assay:

  • Pre-incubate antibody with recombinant KBTBD8 protein or immunogenic peptide

  • Loss of signal confirms specificity

• Molecular weight verification:

  • Confirm detection of expected 69 kDa band in Western blots

  • Check for absence of non-specific bands

• Subcellular localization assessment:

  • Verify KBTBD8 expression pattern (e.g., nuclear during GV, concentrated at spindle poles during MI and MII phases in oocytes)

How can KBTBD8 antibodies be utilized to investigate its role in epithelial ovarian cancer?

Building on published methodologies , researchers can employ KBTBD8 antibodies to:

• Assess expression correlation with malignancy:

  • Immunohistochemistry on tissue microarrays containing various grades of ovarian cancer samples

  • Quantitative scoring of KBTBD8 staining intensity and proportion

  • Statistical analysis correlating expression with clinical parameters

• Investigate mechanistic pathways:

  • Co-immunoprecipitation to identify cancer-specific binding partners

  • Western blot analysis of downstream signaling molecules following KBTBD8 manipulation

  • Phosphorylation state analysis of key kinases (e.g., Erk1/2, Aurora A)

• Functional consequence assessment:

  • KBTBD8 knockdown combined with proliferation assays

  • Migration and invasion assays following antibody-mediated depletion

  • Xenograft models with KBTBD8 manipulation and subsequent IHC analysis

• Therapeutic target validation:

  • Combination of KBTBD8 antibodies with small molecule inhibitors

  • Assessment of synergistic effects on cancer cell viability

What are the technical considerations when using KBTBD8 antibodies to study oocyte maturation and fertility?

Based on research findings , researchers should consider:

• Developmental stage-specific analysis:

  • Use immunofluorescence to track KBTBD8 localization during meiotic stages

  • Compare expression patterns between GV, MI, and MII stages

  • Correlate with PKM1/PKM2 expression patterns

• Co-localization studies:

  • Dual immunofluorescence with markers for:

    • Spindle pole components

    • Mitochondria

    • PKM isoforms

• Signaling pathway assessment:

  • Western blot analysis of the KBTBD8→Erk1/2→Aurora A→PKM1 axis

  • Pharmacological inhibitor studies combined with KBTBD8 antibody staining

• Functional consequence analysis:

  • Microinjection of KBTBD8 antibodies for acute depletion

  • Assessment of:

    • Mitochondrial distribution

    • ATP levels

    • Membrane potential

    • Apoptosis rates

    • ROS generation

• Specificity controls:

  • Include PKM2 detection as an internal control (remains unchanged after KBTBD8 depletion)

  • Use mRNA analysis to complement protein-level studies

What are the optimal protocols for using KBTBD8 antibodies in Western blotting?

Based on validated methodologies :

Sample Preparation:

• Use RIPA buffer with protease and phosphatase inhibitors

• For tissue samples: 10-20 μg total protein per lane

• For cell lines: lysate from approximately 5×10^5 cells per lane

Electrophoresis and Transfer:

• 8-10% SDS-PAGE gels are suitable for resolving the 69 kDa KBTBD8 protein

• Transfer to PVDF or nitrocellulose membranes (0.45 μm pore size)

Antibody Incubation:

• Blocking: 5% non-fat milk or BSA in TBST, 1 hour at room temperature

• Primary antibody: 1:1000 dilution in blocking buffer, overnight at 4°C

• Secondary antibody: 1:5000-1:10000 dilution, 1 hour at room temperature

Detection:

• Enhanced chemiluminescence (ECL) substrate

• Expected band size: 69 kDa

Troubleshooting Tips:

• High background: Increase washing steps, reduce antibody concentration

• No signal: Confirm protein loading, increase exposure time, check transfer efficiency

• Multiple bands: Optimize blocking conditions, reduce antibody concentration

• Unexpected band size: Verify tissue-specific isoforms, check for post-translational modifications

How can I optimize KBTBD8 antibody use for immunofluorescence in studying subcellular localization?

For effective immunofluorescence studies of KBTBD8:

Fixation and Permeabilization:

• For cultured cells: 4% paraformaldehyde (15 min), followed by 0.2% Triton X-100 (10 min)

• For oocytes: 2.5% paraformaldehyde (30 min), followed by 0.5% Triton X-100 (20 min)

Antibody Dilutions:

• Primary antibody: Start with 1:200-1:400 dilution

• Secondary antibody: 1:500-1:1000 dilution of fluorophore-conjugated antibody

Controls:

• Include KBTBD8-depleted samples as negative controls

• Include nuclear counterstain (DAPI/Hoechst)

• Include cytoskeletal markers for co-localization studies

Microscopy Settings:

• Use confocal microscopy for precise subcellular localization

• For oocytes, Z-stack imaging is recommended

• For specific localization patterns:

  • Nuclear during GV stage

  • Spindle poles during MI and MII stages

Image Analysis:

• Quantify fluorescence intensity using ImageJ or similar software

• Perform co-localization analysis when using multiple markers

How do I interpret conflicting KBTBD8 expression data between different experimental approaches?

When facing conflicting KBTBD8 expression data:

• Consider methodological differences:

  • Antibody epitope differences: N-terminal vs. C-terminal antibodies may detect different isoforms

  • Detection techniques vary in sensitivity: Western blot vs. immunofluorescence vs. qPCR

  • Sample preparation can affect epitope accessibility

• Biological variables to consider:

  • Cell/tissue type-specific expression patterns

  • Developmental stage variations: KBTBD8 shows stage-specific localization in oocytes

  • Disease state influences: KBTBD8 is upregulated in ovarian cancer

  • Subcellular compartmentalization may affect detection

• Validation approaches:

  • Use multiple antibodies targeting different epitopes

  • Combine protein and mRNA detection methods

  • Include positive and negative controls in each experiment

  • Perform knockdown/overexpression validation

• Data reconciliation framework:

What analytical approaches should be used to quantify changes in KBTBD8 expression in complex experimental designs?

For rigorous quantification of KBTBD8 expression changes:

• Western blot quantification:

  • Normalize KBTBD8 band intensity to loading controls (β-actin, GAPDH)

  • Use at least three biological replicates

  • Apply appropriate statistical tests (t-test for two groups, ANOVA for multiple groups)

  • Report fold changes with error bars

• Immunohistochemistry scoring:

  • Use standardized scoring systems combining intensity and proportion

  • Have multiple independent observers score samples blindly

  • Apply appropriate statistical methods for ordinal data

  • Consider automated image analysis for objectivity

• RNA expression analysis:

  • Compare multiple reference genes for normalization

  • Use both absolute and relative quantification methods

  • Validate with protein-level measurements

  • Apply appropriate statistical tests for RNA-seq data (DESeq2, edgeR)

• Pathway analysis integration:

  • Combine KBTBD8 expression data with pathway components (e.g., Erk1/2, Aurora A, PKM1)

  • Use correlation analysis to identify relationships

  • Apply pathway enrichment analysis to RNA-seq data

  • Create mechanistic models to explain observed phenotypes

How can KBTBD8 antibodies facilitate research into novel therapeutic targets for epithelial ovarian cancer?

KBTBD8 antibodies can advance ovarian cancer therapeutic research through:

• Target validation strategies:

  • Use antibodies to screen patient-derived xenografts for KBTBD8 expression

  • Correlate expression with treatment response and patient outcomes

  • Identify specific subtypes of EOC with KBTBD8 dependency

• Drug development approaches:

  • Develop high-throughput screening assays using KBTBD8 antibodies

  • Identify small molecules that disrupt KBTBD8-substrate interactions

  • Use antibodies to verify target engagement in drug candidate testing

• Combination therapy exploration:

  • Assess KBTBD8 expression changes following standard chemotherapy

  • Identify synergistic approaches targeting KBTBD8-dependent pathways

  • Develop biomarker strategies for patient stratification

• Mechanistic investigations:

  • Map comprehensive interaction networks using antibody-based proteomics

  • Identify tissue-specific substrates in ovarian cancer cells

  • Explore the KBTBD8→Erk1/2→Aurora A signaling axis as a multi-target approach

What methodological advances would improve the study of KBTBD8 in developmental and reproductive biology?

Advanced methodologies that could enhance KBTBD8 research include:

• Single-cell analysis approaches:

  • Single-cell protein analysis using antibody-based methods

  • Correlation with single-cell transcriptomics

  • Spatial mapping of KBTBD8 expression in reproductive tissues

• In vivo imaging techniques:

  • Development of fluorescent-tagged antibody fragments for live imaging

  • Intravital microscopy to track KBTBD8 dynamics during oocyte maturation

  • Correlative light-electron microscopy for ultrastructural localization

• Proximity labeling approaches:

  • BioID or APEX2 fusion to KBTBD8 to identify proximal interactors

  • Combined with mass spectrometry for comprehensive interaction mapping

  • Validation using conventional co-IP with KBTBD8 antibodies

• CRISPR-based manipulation:

  • Endogenous tagging of KBTBD8 for live visualization

  • Domain-specific mutations to dissect function

  • Tissue-specific conditional knockouts combined with antibody validation

  • Base editing to introduce disease-associated mutations

• Organoid and 3D culture systems:

  • Developing reproductive tissue organoids to study KBTBD8 function

  • Antibody-based tracking in differentiation models

  • Patient-derived organoids for personalized medicine approaches